PTHS News & Events

Pelthos Therapeutics announced John Gay has been appointed CFO, effective April 10. Gay succeeds Francis Knuettel II, who served as Pelthos' CFO since July 2025. Gay has served as Senior Vice President, Finance & Accounting at Pelthos since 2025. He has more than 25 years of public company finance and accounting experience.

Pelthos Therapeutics announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos' subsidiary Channel Pharmaceutical Corporation owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary.